کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5548869 1556597 2017 18 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Antibody therapies in CNS diseases
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی علوم اعصاب رفتاری
پیش نمایش صفحه اول مقاله
Antibody therapies in CNS diseases
چکیده انگلیسی


- Review with special emphasis on the use of antibodies for brain disorders.
- Sufficient exposure in the central nervous system is the major hurdle.
- The blood-brain barrier limits the delivery of antibodies to the brain.
- Approaches to bypassing the blood-brain barrier.

Therapeutic antibodies have essentially been banned from the central nervous system, and are so far limited to use mainly in multiple sclerosis. This is primarily due to the fact that antibody penetration across the blood-brain barrier is very limited, with about only 0.1% of circulating antibodies estimated to reach the brain at steady-state concentration. Nonetheless, advances are being made with conventional antibodies, showing that minimal exposure can act centrally to mediate therapeutic effects. Immunotherapy in Alzheimer's disease is a noteworthy example where antibodies against amyloid-β are able to reduce brain plaque pathology in preclinical models and humans. However, the advances in using antibodies directed at brain targets have also demonstrated impediments of low brain exposure in achieving clinical benefits, spurring increased attention in technologies designed to improve brain exposure of antibodies. Here we review antibodies in clinical trials for central nervous system disorders. Moreover, we describe some of the efforts to improve the therapeutic efficacy of antibodies by enhancing delivery across the blood-brain barrier.This article is part of the Special Issue entitled “Beyond small molecules for neurological disorders”.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neuropharmacology - Volume 120, 1 July 2017, Pages 38-55
نویسندگان
, ,